Edwards Lifesciences (NYSE:EW) VP Sells $971,384.40 in Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Donald Bobo, Jr. sold 11,340 shares of the business’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $85.66, for a total transaction of $971,384.40. Following the transaction, the vice president owned 31,870 shares in the company, valued at approximately $2,729,984.20. The trade was a 26.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Edwards Lifesciences Stock Down 0.3%

EW stock opened at $84.55 on Friday. The stock has a market capitalization of $49.06 billion, a P/E ratio of 36.44, a price-to-earnings-growth ratio of 3.45 and a beta of 0.95. The firm has a 50-day moving average price of $85.01 and a 200-day moving average price of $80.25. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12 month low of $65.94 and a 12 month high of $87.89.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The business had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter last year, the firm posted $0.67 EPS. Edwards Lifesciences’s revenue was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. As a group, equities research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of EW. Level Four Advisory Services LLC grew its stake in Edwards Lifesciences by 3.7% during the 3rd quarter. Level Four Advisory Services LLC now owns 3,301 shares of the medical research company’s stock valued at $257,000 after acquiring an additional 119 shares in the last quarter. Colonial Trust Co SC increased its holdings in shares of Edwards Lifesciences by 0.4% in the third quarter. Colonial Trust Co SC now owns 32,196 shares of the medical research company’s stock valued at $2,504,000 after purchasing an additional 120 shares in the last quarter. Parkside Financial Bank & Trust lifted its stake in shares of Edwards Lifesciences by 9.8% in the 2nd quarter. Parkside Financial Bank & Trust now owns 1,455 shares of the medical research company’s stock valued at $114,000 after purchasing an additional 130 shares during the period. Prosperity Consulting Group LLC grew its stake in Edwards Lifesciences by 3.2% in the second quarter. Prosperity Consulting Group LLC now owns 4,304 shares of the medical research company’s stock valued at $337,000 after acquiring an additional 132 shares during the period. Finally, Howard Capital Management Inc. lifted its stake in Edwards Lifesciences by 3.3% in the 3rd quarter. Howard Capital Management Inc. now owns 4,136 shares of the medical research company’s stock valued at $322,000 after acquiring an additional 132 shares in the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently commented on EW. JPMorgan Chase & Co. raised Edwards Lifesciences from a “neutral” rating to an “overweight” rating and increased their price target for the company from $90.00 to $100.00 in a research note on Thursday, December 18th. Robert W. Baird set a $87.00 price target on Edwards Lifesciences and gave the stock a “neutral” rating in a research report on Tuesday, December 16th. UBS Group set a $92.00 price objective on Edwards Lifesciences in a research note on Friday, December 5th. Evercore ISI reaffirmed an “outperform” rating and set a $94.00 price objective on shares of Edwards Lifesciences in a research report on Monday. Finally, Wall Street Zen downgraded shares of Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research report on Monday, September 29th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $94.27.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.